Related Experiment Video
Updated: Sep 19, 2025
11:11
Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells
Published on: April 25, 2018
8.3K
EZH2: A Crucial Competing Endogenous RNA in Cancer Research-A Scoping Review
Sadra Salehi-Mazandarani1, Sharareh Mahmoudian-Hamedani1, Ziba Farajzadegan2
1Department of Genetics and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Advanced Biomedical Research
|June 16, 2025
Summary
Competing endogenous RNAs (ceRNAs) regulate Enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) in cancer. This review identifies 66 ceRNA axes involving EZH2, highlighting their therapeutic potential in cancer treatment.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- Competing endogenous RNAs (ceRNAs) are crucial regulators in cancer progression.
- Enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) acts as a ceRNA with a dual role in cancer, presenting a potential therapeutic target.
- Understanding EZH2's ceRNA functions is vital for advancing clinical cancer treatment.
Purpose of the Study:
- To conduct a scoping review of experimentally validated ceRNA axes involving EZH2 in human cancers.
- To identify and categorize the types of RNAs (miRNAs, lncRNAs, mRNAs, circRNAs) participating in these axes.
- To highlight frequently observed ceRNA axes and their components for potential therapeutic targeting.
Main Methods:
- Systematic search of multiple online databases for relevant studies.
- Inclusion of only experimentally validated ceRNA axes involving EZH2.
- Data extraction and categorization of identified RNA molecules and their interactions.
Main Results:
- Identified 66 unique ceRNA axes involving EZH2.
- Cataloged 30 microRNAs (miRNAs), 32 long non-coding RNAs (lncRNAs), 9 messenger RNAs (mRNAs), and 14 circular RNAs (circRNAs).
- Observed recurrent axes like SPRY4-IT1-miR-101-3p-EZH2 and XIST-miR-101-3p-EZH2 across multiple cancer types. Frequent competitors included miR-101-3p, miR-144-3p, miR-124-3p, SPRY4-IT1, XIST, SNHG6, HOXA11-AS, MALAT1, and TUG1.
Conclusions:
- EZH2-containing ceRNA axes are diverse and prevalent in human cancers.
- These axes represent promising targets for novel cancer therapies.
- Further research is necessary to elucidate the precise roles and clinical applicability of these ceRNA networks.
Related Concept Videos
02:28Leaky Scanning
5.2K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.2K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:55The Nucleolus
9.2K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
9.2K
03:18Non-LTR Retrotransposons
11.9K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.9K
02:49Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
02:39lncRNA - Long Non-coding RNAs
9.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K